CardioDialysis Technology Aims to Transform Cardiovascular Disease Treatment Through Simplified Blood Purification

Cardiovascular disease remains the leading cause of death worldwide, with therapies primarily focused on reducing major adverse cardiovascular events. While LDL-C reducing statins decrease MACE by approximately 25%, lipoprotein apheresis technologies that filter LDL-C and Lipoprotein(a) from the bloodstream have demonstrated 75-95% reductions in MACE incidence according to the American Heart Association. However, widespread adoption of these technologies has been limited by complex, multi-component designs lacking global delivery infrastructure.

CardioDialysis represents a breakthrough in subtractive medicine as the first technology to fully integrate plasma separation and therapeutic adsorption within a single device. This integration enables continuous broad-spectrum clearance of both inflammatory and pathogenic molecules from the entire bloodstream. The technology's design allows deployment on dialysis machines already located in hospitals and clinics, addressing the infrastructure limitations that have constrained existing treatments.

The contrast with current technologies is significant. The FDA-approved Kaneka LIPOSORBER procedure, which has administered approximately 600,000 treatments to more than 6,000 patients worldwide, requires multiple components including a plasma separation column, two LIPOSORBER cartridges, custom blood tubing sets, a blood warmer, replacement fluids, regeneration fluids, waste bags, and multiple pumps. This complexity limits access to fewer than 60 specialized apheresis centers in the United States.

In comparison, CardioDialysis functions as a fully integrated single-component device deployable on dialysis machines already present in more than 5,000 hospitals and 7,500 dialysis clinics in the United States alone. Beyond simplified deployment, CardioDialysis addresses a broader range of cardiovascular disease targets, processes the bloodstream with greater efficiency, and eliminates the need for replacement fluids, additional pumps, or auxiliary components required by existing systems.

The potential impact of this technology is substantial given that 15-20% of major adverse cardiovascular events result in death. Successful clinical advancement of CardioDialysis could save thousands of lives annually by overcoming the limitations of single-target drugs and providing more accessible, effective treatment. The technology's ability to simultaneously reduce inflammatory mediators fueling cardiovascular disease progression while lowering cholesterol-transporting lipoproteins represents a significant advancement in cardiovascular care.

Additional information about the company's development pipeline and technology can be found at https://www.SigynTherapeutics.com. The original press release containing forward-looking statements about the technology's development and potential risks is available at https://www.newmediawire.com.